The Modernizing Opioid Treatment Access Act 2.0 of 2026 allows licensed addiction medicine specialists to prescribe methadone for opioid use disorder to be dispensed directly through pharmacies, rather than requiring patients to visit traditional treatment clinics. Under this bill, these practitioners must use electronic prescribing and can only dispense liquid or dispersible tablet formulations, while pharmacies do not need separate registration to handle these prescriptions. The law also permits telemedicine for maintenance or detoxification treatment and requires doctors to obtain informed consent from patients regarding how privacy protections differ between clinic and pharmacy settings. Additionally, the Attorney General can revoke a doctor's registration if a state requests it, and the Drug Enforcement Administration must report annually on the number of registered providers and pharmacies involved in the program.
The Residential Recovery for Seniors Act expands Medicare coverage to include three specific levels of residential treatment for substance use disorders: clinically managed low-intensity, clinically managed high-intensity, and medically managed services. To qualify for this coverage, facilities must meet strict standards regarding staffing, clinical assessments, and adherence to evidence-based criteria developed by recognized medical associations. The bill also establishes a new payment system that reimburses these facilities on a per-day basis, starting in fiscal year 2027, with rates initially set to cover 100% of their estimated costs.
The IBOGAINE Act aims to accelerate the development and approval of ibogaine and similar compounds for treating addiction, trauma, and serious mental illnesses by modifying federal drug laws. It creates a new voucher system that grants sponsors of breakthrough mental health drugs priority review by the FDA, while also establishing special registration rules to allow physicians to legally administer Schedule I substances to eligible patients under the "right to try" law. The legislation further directs the Department of Veterans Affairs to create a dedicated senior official and workforce plan for emerging therapies, mandates timely rescheduling of ibogaine from Schedule I to Schedule II, and requires federal agencies to share clinical trial data to speed up the approval process.
This Senate resolution designates June 6, 2026, as National Naloxone Awareness Day to highlight the importance of naloxone in reversing opioid overdoses. The measure aims to educate the public, healthcare providers, and first responders on how to recognize overdose signs and safely administer the medication. It also encourages federal, state, and local governments along with private organizations to support efforts that increase access to and distribution of naloxone.
The Medicaid RAC Improvement Act of 2026 strengthens oversight of the Medicaid Recovery Audit Contractor program to better detect and recover incorrect payments. It requires the Centers for Medicare and Medicaid Services to establish clear communication rules for when state program exceptions expire and mandates detailed annual reports on audit results, including amounts recovered and underpayments. The bill also expands the program to include Medicaid managed care plans, requiring these organizations to allow audits of their claims and cooperate with recovery efforts. Additionally, the legislation directs the government to study barriers preventing states from participating in the program and to run a five-year demonstration project to increase state involvement. Finally, it clarifies that audits can review payments made up to four years prior to the current fiscal year.
This bill directs the Secretary of Education to create and share evidence-based model plans for mental health and suicide prevention specifically for colleges and universities. In partnership with the Substance Abuse and Mental Health Services Administration, the government will provide technical assistance to schools that wish to adopt these models, while also considering existing state efforts and collaborating with various community and student groups. The legislation requires regular updates to these model plans every five years and mandates periodic reports to Congress on the program's progress. Importantly, the bill clarifies that these measures are voluntary guidelines and do not impose new legal requirements on higher education institutions.
The School Access to Naloxone Act of 2026 authorizes federal grants to help public and private elementary and secondary schools provide emergency treatment for opioid overdoses. To receive funding, schools must establish a program where trained staff, such as nurses or designated administrators, can administer naloxone and other reversal drugs from an easily accessible supply. The bill requires that these staff members receive proper medical training and certification, and it mandates that state attorneys general confirm laws exist to protect these individuals from civil liability when administering the drugs. This legislation aims to reduce opioid overdose deaths by ensuring schools have the necessary resources and legal safeguards to respond quickly to emergencies.
The Prior Authorization Reform for Autoimmune and Blood Disorders Act requires group health plans and health insurers to cover specific medications for autoimmune diseases, hemophilia, and Von Willebrand disease without restricting how they are administered. To improve access, the bill limits prior authorization requirements for these drugs to no more than once every 12 months, unless the medication is short-term, classified as an opioid or benzodiazepine, or carries a specific government-mandated risk management strategy. These rules apply to plans governed by federal laws including ERISA, the Public Health Service Act, and the Internal Revenue Code, with coverage beginning for plan years starting on or after January 1, 2027.
The Gambling Disorder Health Study Act directs the Secretary of Health and Human Services to conduct research on gambling disorder, a behavioral addiction recognized by the American Psychiatric Association. This initiative aims to fill a current gap in federal oversight by funding studies on the causes, impacts, and treatments of gambling addiction, particularly in light of recent state legalization of sports betting. The program will involve collaboration with various federal agencies, academic institutions, and nonprofit organizations to analyze how different forms of gambling, including online platforms and mobile apps, affect individuals and communities. Findings from this research will be reported annually to Congress, which will then review recommendations for public health actions and policy changes. Funding for these efforts is authorized from 2027 to 2029, based on a percentage of taxes collected from gambling activities.
This bill clarifies how drugs are defined and scheduled under the Controlled Substances Act to better balance public safety with medical access. It updates legal definitions for terms like "accepted medical use," "dependence," and "abuse" to include scientific research and evidence-based evaluations from state medical regulators. Additionally, it requires the Attorney General to defer to the Secretary of Health and Human Services on scientific assessments and to consider a drug's potential benefits to society when deciding on its schedule. These changes directly affect how the federal government classifies substances and aims to ensure that scheduling decisions are based on rigorous science rather than solely on the potential for abuse.
